Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Lymphedema; and very common findings: Hydrocele testis.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Lymphedema |
ANGPT2 encodes angiopoietin 2 (496 aa). Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling. Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. Highest expression in Artery Tibial (17.7 TPM) and Adipose Subcutaneous (13.3 TPM).
Lymphatic malformation 10 is associated with mutations in the ANGPT2 gene on chromosome 8.
ANGPT2 is classified as a druggable target (Druggable Genome, Fibrinogen, and Kinase categories) with score 5.2.
Genetic testing for ANGPT2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for lymphatic malformation 10 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 1 very common feature.
No clinical trials have been registered for lymphatic malformation 10.
136 publications have been identified in PubMed for lymphatic malformation 10. Kisho has analyzed 52 by research type. Research spans Review / Meta-Analysis (27%), Case Report / Case Series (19%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 14 | 27% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:55 PM UTC
Online Mendelian Inheritance in Man
Patient case studies
10 |
19% |
Disease patterns and progression | 8 | 15% |
Testing and diagnosis research | 7 | 13% |
Laboratory research | 6 | 12% |
Clinical study results | 4 | 8% |
New treatment approaches | 3 | 6% |
Singh S (2026). [PMID: 41830665](https://pubmed.ncbi.nlm.nih.gov/41830665/). *Int J Pediatr Otorhinolaryngol*. [Case Report / Case Series]
Taniguchi A (2026). [PMID: 42217144](https://pubmed.ncbi.nlm.nih.gov/42217144/). *Paediatr Drugs*. [Epidemiology / Natural History]
Loeser JH (2026). [PMID: 41022105](https://pubmed.ncbi.nlm.nih.gov/41022105/). *Rofo*. [Diagnostic / Biomarker]
Klein WM (2026). [PMID: 42024244](https://pubmed.ncbi.nlm.nih.gov/42024244/). *Pediatr Radiol*. [Review / Meta-Analysis]
Zhou Z (2025). [PMID: 40102890](https://pubmed.ncbi.nlm.nih.gov/40102890/). *Orphanet J Rare Dis*. [Review / Meta-Analysis]
Ricciardelli AR (2025). [PMID: 39899215](https://pubmed.ncbi.nlm.nih.gov/39899215/). *Angiogenesis*. [Review / Meta-Analysis]
van den Brink VC (2025). [PMID: 40835771](https://pubmed.ncbi.nlm.nih.gov/40835771/). *Eur J Pediatr*. [Basic Science / Preclinical]
Zhang Y (2025). [PMID: 40606337](https://pubmed.ncbi.nlm.nih.gov/40606337/). *Quant Imaging Med Surg*. [Diagnostic / Biomarker]
Hollman D (2025). [PMID: 41170851](https://pubmed.ncbi.nlm.nih.gov/41170851/). *J Cutan Med Surg*. [Review / Meta-Analysis]
Shiraishi M (2025). [PMID: 40358370](https://pubmed.ncbi.nlm.nih.gov/40358370/). *Lymphology*. [Epidemiology / Natural History]